NEW YORK (GenomeWeb) – Agilent Technologies and SISCAPA Assay Technologies said today that they have signed a non-exclusive agreement to provide complete workflows for targeted protein quantitation.
The workflows combine SAT's SISCAPA reagents for immunoenrichment mass spec-based protein quantitation with Agilent's Bravo automated liquid handling platform for sample prep and LC/MS systems, including Agilent's RapidFire high-throughput LC/MS system, for quantitative analysis.
Short for stable isotope standards and capture by anti-peptide antibodies, SISCAPA combines antibody-based peptide enrichment with mass spectrometry, increasing the sensitivity of mass spec instruments, which by themselves are often not sensitive enough to detect low-abundance proteins in complex samples.
By providing samples enriched for the peptides of interest, the technique also reduces the length of the LC gradients required prior to mass spec analysis, thereby boosting assay throughput.
According to the companies, the automated version of the assay supports preparation of 400 multiplexed samples per working day.
"[T]his partnership offers customers a truly enabling workflow to execute targeted protein assays with a throughput and precision that were previously impossible,” Yvonne Linney, vice president and general manager for Agilent’s Life Science Solutions Division, said in a statement.
Financial and other terms of the agreement were not disclosed.